2023-11-04 17:16:00
Par Paul Lesigne
Published on 4 Nov 23 at 6:16 p.m. See my news Follow Le Pays d’Auge
Friday October 27, 2023, during the presentation of its quarterly results, Sanofi announced its intention to separate from its Consumer Health division.
This includes food supplements and various products sold without a prescription, such as Doliprane. This separation should take place “no earlier than the fourth quarter of 2024”, through “the creation of a listed entity whose headquarters will be in France”, specifies the pharmaceutical group.
The objective for Sanofi is to accelerate innovation and focus on rare diseases, immuno-inflammation, hematology, vaccines and certain areas of oncology.
Not completely a surprise
The Sanofi site in Lisieux (Calvados) is directly affected by this news: Doliprane is produced there in all its forms. “We learned it Friday morning, like everyone else,” breathes Christophe Quillet.
Despite everything, the CGT union representative is not surprised. In 2019, Sanofi created Opella, an entity bringing together all over-the-counter medications and dietary supplements. Then, in 2022, the headquarters of this subsidiary were transferred from Gentilly (Val-de-Marne), headquarters of Sanofi France, to Neuilly-sur-Seine (Hauts-de-Seine).
The first warning signs of separation:
“All the major global pharmaceutical groups do it. Since 2018, they have all separated from their CHC (Consumer Health Service, editor’s note) branch. There were only two left in the world, Sanofi and Bayer. We suspected that this would eventually happen, and that we would one day be taken out of Sanofi. On the other hand, we didn’t expect it now. We were rather expecting something around 2025, given that Sanofi’s major strategies end that year. »
Christophe Quillet
An investment of 20 million euros in Lisieux
And the timing may have surprised people, while two weeks earlier, Audrey Derveloy, president of Sanofi France, announced on France Inter an investment of 20 million euros in the Lexovian factory, to produce 140 million additional boxes of Doliprane per year by 2025: “In large groups, investments have been planned for 2, 3 or 4 years. The money is provisioned, so they put it on the table, that’s how it is. We shouldn’t be surprised, it’s something common,” says the union representative.
Videos: currently on Actu
The pharmaceutical group’s announcement caused “a lot of concern for employees”, notes Christophe Quillet. What will this change for the Lisieux site? “Right now, not much. We will remain Sanofi for another year. » But followingwards, “one thing is certain, there will be all company agreements to renegotiate”, predicts the CGT delegate:
“Today, we are getting profit-sharing and participation. Will we receive the same amounts tomorrow? We do not know. »
Christophe Quillet
“The security of a large group”
The Sanofi factory in Lisieux has “250 employees on average, and around sixty temporary workers”. Doliprane, “which has existed for almost 60 years”, is a sure value on the market and is the strength of the Lexovian site for the future.
Not enough, however, to completely reassure employees. By leaving Sanofi, “you no longer have the security of a large group, this is not insignificant”, underlines Christophe Quillet: “Everyone’s wish is to stay in the Sanofi group. »
Follow all the news from your favorite cities and media by subscribing to Mon Actu.
1699153417
#Sanofi #separate #Doliprane #concerns #Lisieux #factory